Managing antipsychotic-induced acute and chronic akathisia

Drug Safety

Volumn 22, Issue 1, 2000, Pages 73-81

  Miller, Carl H ^a   Fleischhacker, W Wolfgang ^b  

^a Abteilung Anast/Allge Intensivmed   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; NEUROLEPTIC AGENT; PIRACETAM; PROPRANOLOL; RITANSERIN; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AKATHISIA; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0033963172     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200022010-00006     Document Type: Review

References (71)

1. 1. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systemic investigation of acute psychiatric inpatient admission. Br J Psychiatry 1983; 143 139-50
2. 2. Fleischhacker WW, Miller CH, Schett P, et al. The Hillside Akathisia Scale: a reliability comparison of the English and German versions. Psychopharmacology (Berl) 1991; 105: 141-4
3. 3. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874-8
4. 4. Sachdev P. The epidemiology of drug induced akathisia: part 1: acute akathisia. Schizophr Bull 1995; 21: 431-49
5. 5. Munetz MR, Cornes CL. Distinguishing akathisia and tardive dyskinesia. J Clin Psychopharmacol 1983; 3: 343-50
6. 6. Stahl SM. Akathisia and tardive dyskinesia: changing concepts. Arch Gen Psychiatry 1985; 42: 166-9
7. 7. Sachdev P. Akathisia and restlessness. Melbourne: Press Syndicate of the University of Cambridge, 1995
8. 8. Sachdev P. Research diagnostic criteria for drug induced akathisia: conceptualization, rationale and proposal. Psychopharmacology 1994; 114: 181-6
9. 9. National Institute of Mental Health, and Psychopharmacology survey center collaborative study group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 161-246
10. 10. Ayd FJ. High potency neuroleptics and akathisia. J Clin Psychopharmacol 1984; 4: 227-30
11. 11. van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036-9
12. 12. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admission. Br J Psychiatry 1993; 143: 139-50
13. 13. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug induced akathisia. Arch Gen Psychiatry 1994; 51: 963-74
14. 14. Miller CH, Hummer M, Oberbauer H, et al. Dose escalation influenced the risk of neuroleptic induced akathisia. Eur Neuropsychopharmacol 1997; 7: 51-7
15. 15. Saffermann AZ, Lieberman JA, Pollack S, et al. Akathisia and clozapine treatment. J Clin Psychopharmacol 1993; 13: 286-7
16. 16. Kurz M, Hummer M, Kemmler G, et al. Long term pharmacokinetics of clozapine. Br J Psychiatry 1998; 173: 341-4
17. 17. Cohen BM, Keck PE, Satlin A. Prevalence and severity of akathisia in patients on clozapine. Br J Psychiatry 1991; 29: 1215-9
18. 18. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal sings and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59: 2, 69-75
19. 19. Ayd FJ. A survey of drug induced extrapyramidal reactions. J Am Med Assoc 1961; 175: 1054-60
20. 20. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980; 10: 55-72
21. 21. Goldstein J, Litwin L, Malick J. Ritanserin increases spontaneous activity of A9 and A10 dopamine neurons [abstract]. Fed Proc 1987; 46: 966
22. 22. Wiesel FA. Effects of high dose propranolol treatment on dopamine and norepinephrine metabolism in regions of rat brain. Neurosci Lett 1976; 2: 35-8
23. 23. Bersani G, Grispini A, Marini S, et al. Neuroleptic induced extrapyramidal side effects: clinical perspectives with ritanserin, a new selective 5HT2 receptor blocking agent. Curr Ther Res 1986; 40: 492-9
24. 24. Bersani G, Grispini A, Marini S, et al. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrinc and placebo. Clin Neuropharmacol 1990; 13: 500-6
25. 25. Miller CH, Fleischhacker WW, Ehrmann H, et al. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373-6
26. 26. Lipinski Jr JF, Mallya G, Zimmermann P, et al. Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychopharmacol 1989; 50: 339-42
27. 27. Sachdev P. The Identification and management of drug induced akathisia. CNS Drugs 1995; 4: 28-46
28. 28. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 1988; 45: 79-91
29. 29. Lipinski Jr JF, Zubenko GS, Barreira PJ, et al. Propanolol in the treatment of neuroleptic induced akathisia. Lancet 1983; I: 685-6
30. 30. Lipinski Jr JF, Zubenko GS, Cohen BM, et al. Propanolol in the treatment of neuroleptic induced akathisia. Am J Psychiatry 1984; 141: 412-5
31. 31. Adler LA, Angrist B, Peselow E, et al. A controlled assessment of propanolol in the treatment of neuroleptic induced akathisia. Br J Psychiatry 1986; 149: 42-5
32. 32. Adler LA, Angrist B, Peselow E, et al. Clonidine in neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 235-6
33. 33. Adler LA, Angrist B, Peselow E. Efficacy of propanolol in neuroleptic induced akathisia. J Clin Psychopharmacol 1985; 5: 164-6
34. 34. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic induced akathisia. J Clin Psychopharmacol 1990; 10: 12-21
35. 35. Deron C, Wlink W, Buylaet W, et al. Which beta blocker for the restless legs? Lancet 1984; I: 875
36. 36. Reiter S, Adler LA, Erle S, et al. Neuroleptic induced akathisia treated with pindolol. Am J Psychiatry 1987; 144: 1241-2
37. 37. Adler LA, Reiter S, Angrist B. Pindolol and propanolol in neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 1241-2
38. 38. Zubenko GS, Cohen BM, Lipinski Jr JF, et al. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 253-9
39. 39. Dumon JP, Catteau J, Lavin F. Randomized, double blind, crossover, placebo controlled comparison of propanolol and betaxolol in the treatment of neuroleptic induced akathisia. Am J Psychiatry 1992; 149: 647-50
40. 40. Dupuis B, Catteau J, Dumon JP. Comparison of propanolol, sotalol and betaxolol in the treatment of neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 802-5
41. 41. Wells BG, Cold JA, Marken PA. A placebo controlled trial of nandolol in the treatment of neuroleptic induced akathisia. J Clin Psychiatry 1991; 52: 255-60
42. 42. Reiter S, Adler LA, Erle S. Atenolol and propanolol in neuroleptic induced akathisia. J Clin Psychopharmacol 1987; 7: 279-80
43. 43. Ekbom A. Irritable legs. Acta Med Stand 1944; 118: 197-8
44. 44. Morgan LK. Restless limbs: a commonly overlooked symptom controlled by valium. Med J Aust 1967; 589-94
45. 45. Bartels M, Heide K, Mann K, Treatment of akathisia with lorazepam: an open trial. Pharmacopsychiatry 1987; 20: 51-3
46. 46. Kutcher S, Williamson P, MacKenzie S, et al. Successful clonazepam treatment of neuroleptic induced akathisia in older adolescents and young adults: a double blind study. J Clin Psychopharmacol 1989; 9: 403-6
47. 47. Kutcher S, MacKenzie S, Galarraga J, et al. Clonazepam treatment of adolescents with neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 823-4
48. 48. Donlon PT. The therapeutic use of diazepam for akathisia. Psychosomatics 1973; 14: 222-5
49. 49. Gagrat D, Hamilton J, Belmaker R. Intravenous diazepam in the treatment of neuroleptic induced dystonia or akathisia. Am J Psychiatry 1978; 135: 1232-3
50. 50. van Putten T, Mutalipassi LR, Malkin MD. Phenothiazine induced decompensation. Arch Gen Psychiatry 1974; 30: 102-5
51. 51. Friis T, Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic induced akathisia, parkinsonism and hyperkinesia: a double blind cross over study with placebo. Acta Psychiatr Scand 1982; 67: 178-87
52. 52. Di Mascio A, Bernardo DL, Greenblatt D, et al. A controlled trial of amantadine in drug induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599-602
53. 53. Sachdev P, Loneragan C. Intravenous benztropine and propanolol challenges in acute neuroleptic induced akathisia. Clin Neuropharmacol 1993; 16: 324-31
54. 54. Adler LA, Peselow E, Rosenthal M, et al. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 1993; 29: 283-6
55. 55. Tune L, Cole JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 1981; 79: 9-15
56. 56. Langer SZ. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 1977; 60: 481-97
57. 57. Adler LA, Reiter S, Corwin J, et al. Differential effects of propanolol and benztropine in patients with neuroleptic induced akathisia. Psychopharmacol Bull 1987; 23: 519-21
58. 58. Gelenberg AJ. Amantadine in the treatment of benztropine refractory extrapyramidal disorders induced by antipsychotic drugs. Curr Ther Res 1978; 22, 375-80
59. 59. Zubenko GS, Barreira PJ, Lipinski Jr JF, Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol 1984; 4: 218-20
60. 60. Fleischhacker WW, Bergman KJ, Pestreich LK, et al. The Hillside Akathisia Scale, a new rating instrument for neuroleptic induced akathisia. Psychopharmacol Bull 1989; 25: 222-6
61. 61. Verbnyi Y, Derzhiruk LP, Moglilevskii AY. Piracetam induced changes in the functional activity of neurons as a possible mechanism for the effects of nootropic agents. Neurosci Behav Physiol 1996; 26 (6): 507-15
62. 62. Kabes J, Sikora J, Pisvejc J, et al. Effects of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatr 1982; 17: 185-92
63. 63. Danel T, Servant D, Goudemand M. Amitriptyline in the treatment of neuroleptic induced akathisia. Biol Psychiatry 1988; 23: 186-8
64. 64. Burke RE, Kang UJ, Jankovic J. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4: 157-75
65. 65. Levin H, Chengappa KN, Kambhampti RK, et al. Should chronic treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53: 248-51
66. 66. Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 1997; 53 (6): 915-29
67. 67. Stein MB, Pohlman ER. Tardive akathisia associated with low dose haloperidole use. J Clin Psychopharmacol 1987; 7: 200-3
68. 68. Yassa R, Iskandar H, Nastase C. Propanolol in the treatment of tardive akathisia: a report of two cases. J Clin Psychopharmacol 1988; 43: 544-7
69. 69. Weiner WJ, Luby ED. Persistent akathisia following neuroleptic withdrawal. Ann Neurol 1983; 13: 466-7
70. 70. Yassa R, Bloom D. Lorazepam and anticholinergics in tardive akathisia. Biol Psychiatry 1990; 27: 463-7
71. 71. Sachdev P, Chee KY. Pharmacological characterization of tardive akathisia. Biol Psychiatry 1990; 28: 809-18